TY - JOUR
T1 - Biologics and postbiologics
T2 - novel immunotherapeutics for the induction and maintenance of remission
AU - van Eden, Willem
AU - Lisse, Jeffrey
AU - Prakken, Berent
AU - Albani, Salvatore
PY - 2010/1
Y1 - 2010/1
N2 - Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.
AB - Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.
UR - http://www.scopus.com/inward/record.url?scp=74149090107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74149090107&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2008.12.010
DO - 10.1016/j.drudis.2008.12.010
M3 - Review article
C2 - 19162218
AN - SCOPUS:74149090107
SN - 1359-6446
VL - 15
SP - 71
EP - 77
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 1-2
ER -